Clinical Trials Browser

Anemia, Refractory, with Excess of Blasts × ivosidenib × 30 days × Clear all

NCT07607418 2026-05-26

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Phase 2 Recruiting

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute